
|Articles|October 23, 2012
FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older
FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
2
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
3
Study Links Live Flu Vaccine With Rise in Pneumococcal Disease
4
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
5





























